BridgeBio Pharma has entered into a strategic partnership with National Resilience (Resilience) for the manufacturing and advancement of two investigational gene therapies, BBP-812 and BBP-631.
Cambrex has concluded the expansion of capacity at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina, US.
Indian pharmaceutical firm Lupin has entered into an agreement to acquire five brands along with associated trademark rights from the units of Menarini -- A. Menarini India Private Limited and A. Menarini Asia-Pacific Holdings.
WuXi XDC has launched new commercial Good Manufacturing Practices (GMP) facilities in Wuxi, Jiangsu Province, China.
Novo Nordisk has launched Wegovy (semaglutide injection) as an adjunctive treatment for obese patients in the UK.
TheracosBio has announced the commercial availability of Brenzavvy (bexagliflozin) oral tablet for the treatment of adults with type 2 diabetes by prescription through the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs).
Astellas Pharma, through its indirect wholly owned subsidiary, Berry Merger Sub, has completed the acquisition of Iveric Bio.
Rosemont Pharmaceuticals has acquired Lucis Pharma, which is a specialist pharmaceutical business in the UK, for undisclosed amount.
Alvotech and Advanz Pharma have extended their strategic partnership for the supply and commercialisation of five biosimilars in Europe.
Nordic pharma company Navamedic ASA has offered $7.2m (SEK75m) to purchase all shares in Sweden-based pharmaceutical firm Sensidose AB.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.